Acute Pyelonephritis Clinical Trial
Official title:
Detection of Causative Agents of Acute Pyelonephritis Using Bacterial Metallophores
The project aims to investigate bacterial metallophores as potential diagnostic markers of acute pyelonephritis and complicated urinary tract infections. These secondary metabolites are excreted by pathogenic microorganims in the course of infection for the uptake of iron and other metallic ions from the host. They are species-specific and can be detected in body fluids (including urine) by mass spectrometry. The potential contribution of this project is a culture-independent method for the diagnosis of the causative microbiological agent.
Acute pyelonephritis (AP) is a clinical syndrome characterized by fever, chills, nausea vomiting and costovertebral angle tenderness, bacteriuria and pyuria. The underlying pathophysiology is based on the presence of microbes in the renal parenchyma which may progress to sepsis. Complicated urinary tract infection (cUTI) is one accompanied by abnormalities of the urinary tract or host factors which make the eradication of the infection difficult. The most common etiological agents include gram-negative enteric rods, i.e. E. coli, Klebsiella pneumoniae; and Enterococcus spp. Empirical antibiotic treatment should be targeted once culture and sensitivity results become available. This usually takes 24-48 hours, occasionally even 72 hours. Inadequate antibiotic treatment leads to higher mortality if the etiological agent is of a multi-drug resistant phenotype. Metallophores are a major virulence factor of bacterial pathogens. These are chelating molecules secreted by the microbe for the uptake of iron, copper, and other metals from the host. E.g., siderophores aim at Fe3+ ions removal from the host protein molecules; the complex then adheres to specific extracellular receptors on the microbial cell and is internalized. Yersiniabactin is another metallophore which binds copper. Proteomic analysis using mass spectrometry has been used in the detection of biomarkers for several pathological conditions: renal failure, post-transplant nephropathy, various malignancies etc. Metallophores can be detected by mass spectrometry. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05905055 -
P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales
|
Phase 3 | |
Not yet recruiting |
NCT05060419 -
Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections
|
Phase 2 | |
Recruiting |
NCT02537847 -
Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Escherichia Coli
|
Phase 2 | |
Completed |
NCT02166476 -
Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP
|
Phase 3 | |
Completed |
NCT03757234 -
IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis
|
Phase 2 | |
Completed |
NCT06141395 -
NGS-Based Assay of Blood Samples of Sepsis Patients for Rapid Bacterial Identification
|
||
Recruiting |
NCT05887908 -
Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis
|
Phase 3 | |
Completed |
NCT02420366 -
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
|
||
Recruiting |
NCT04654507 -
Efficacy of Corticosteroids in Reducing Renal Scarring in Acute Pyelonephritis in Children
|
Phase 3 | |
Completed |
NCT04686318 -
Accuracy of Infection Biomarkers in the Investigation of Patients With Suspected Acute Pyelonephritis
|
||
Completed |
NCT04667195 -
Clinical Characteristics of Acutely Hospitalized Adults With Acute Pyelonephritis
|
||
Completed |
NCT03788967 -
Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
|
Phase 3 | |
Completed |
NCT02168946 -
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
|
Phase 3 | |
Completed |
NCT01096849 -
A Study of Plazomicin Compared With Levofloxacin for the Treatment of Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP)
|
Phase 2 | |
Not yet recruiting |
NCT03630081 -
Study of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
|
Phase 3 | |
Completed |
NCT03445195 -
Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections
|
Phase 2 | |
Completed |
NCT02486627 -
A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP)
|
Phase 3 | |
Completed |
NCT03477422 -
CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) Compared to Meropenem in Complicated Urinary Tract Infections (cUTIs) Caused by ESBL Producing Gram Negative Bacteria
|
Phase 3 | |
Recruiting |
NCT06059846 -
A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
|
Phase 3 | |
Completed |
NCT01928433 -
Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis
|
Phase 2 |